Cargando…
Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on several landmark trials. However, the optimal regim...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021527/ https://www.ncbi.nlm.nih.gov/pubmed/35463306 http://dx.doi.org/10.3389/fonc.2022.734581 |
_version_ | 1784689850629226496 |
---|---|
author | Huang, Runkai Qiu, Zhenbin Zheng, Chunwen Zeng, Ruijie Chen, Wanxian Wang, Simeng Li, Enmin Xu, Yiwei |
author_facet | Huang, Runkai Qiu, Zhenbin Zheng, Chunwen Zeng, Ruijie Chen, Wanxian Wang, Simeng Li, Enmin Xu, Yiwei |
author_sort | Huang, Runkai |
collection | PubMed |
description | Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on several landmark trials. However, the optimal regimen, radiation dose, and surgical intervals are uncertain and the rate of recurrence after neoadjuvant therapy is high. Patients receiving neoadjuvant therapy and reaching a pathological complete response have been reported to have a better survival benefit and a fewer recurrence risk than those non-pathological complete responses. Nevertheless, less than half of patients will reach a pathological complete response after neoadjuvant therapy, and the methods to evaluate the efficacy after neoadjuvant therapy accurately are limited. Immune checkpoint inhibitors have been recommended for the treatments of advanced esophageal cancers. Recently, research has been beginning to evaluate the safety and efficacy of immunotherapy combined with neoadjuvant therapy. Here, we will review and discuss the development of the neoadjuvant therapy of locally advanced esophageal cancers and unsolved clinical problems. |
format | Online Article Text |
id | pubmed-9021527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90215272022-04-22 Neoadjuvant Therapy for Locally Advanced Esophageal Cancers Huang, Runkai Qiu, Zhenbin Zheng, Chunwen Zeng, Ruijie Chen, Wanxian Wang, Simeng Li, Enmin Xu, Yiwei Front Oncol Oncology Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on several landmark trials. However, the optimal regimen, radiation dose, and surgical intervals are uncertain and the rate of recurrence after neoadjuvant therapy is high. Patients receiving neoadjuvant therapy and reaching a pathological complete response have been reported to have a better survival benefit and a fewer recurrence risk than those non-pathological complete responses. Nevertheless, less than half of patients will reach a pathological complete response after neoadjuvant therapy, and the methods to evaluate the efficacy after neoadjuvant therapy accurately are limited. Immune checkpoint inhibitors have been recommended for the treatments of advanced esophageal cancers. Recently, research has been beginning to evaluate the safety and efficacy of immunotherapy combined with neoadjuvant therapy. Here, we will review and discuss the development of the neoadjuvant therapy of locally advanced esophageal cancers and unsolved clinical problems. Frontiers Media S.A. 2022-04-07 /pmc/articles/PMC9021527/ /pubmed/35463306 http://dx.doi.org/10.3389/fonc.2022.734581 Text en Copyright © 2022 Huang, Qiu, Zheng, Zeng, Chen, Wang, Li and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Huang, Runkai Qiu, Zhenbin Zheng, Chunwen Zeng, Ruijie Chen, Wanxian Wang, Simeng Li, Enmin Xu, Yiwei Neoadjuvant Therapy for Locally Advanced Esophageal Cancers |
title | Neoadjuvant Therapy for Locally Advanced Esophageal Cancers |
title_full | Neoadjuvant Therapy for Locally Advanced Esophageal Cancers |
title_fullStr | Neoadjuvant Therapy for Locally Advanced Esophageal Cancers |
title_full_unstemmed | Neoadjuvant Therapy for Locally Advanced Esophageal Cancers |
title_short | Neoadjuvant Therapy for Locally Advanced Esophageal Cancers |
title_sort | neoadjuvant therapy for locally advanced esophageal cancers |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021527/ https://www.ncbi.nlm.nih.gov/pubmed/35463306 http://dx.doi.org/10.3389/fonc.2022.734581 |
work_keys_str_mv | AT huangrunkai neoadjuvanttherapyforlocallyadvancedesophagealcancers AT qiuzhenbin neoadjuvanttherapyforlocallyadvancedesophagealcancers AT zhengchunwen neoadjuvanttherapyforlocallyadvancedesophagealcancers AT zengruijie neoadjuvanttherapyforlocallyadvancedesophagealcancers AT chenwanxian neoadjuvanttherapyforlocallyadvancedesophagealcancers AT wangsimeng neoadjuvanttherapyforlocallyadvancedesophagealcancers AT lienmin neoadjuvanttherapyforlocallyadvancedesophagealcancers AT xuyiwei neoadjuvanttherapyforlocallyadvancedesophagealcancers |